Double vaccine attack: new hope for HPV-Positive throat cancer?
NCT ID NCT05799144
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 17 times
Summary
This study tests whether combining two different HPV vaccines with the immunotherapy drug pembrolizumab can help control advanced oropharyngeal (throat) cancer that has spread or returned. About 54 adults with HPV-positive, PD-L1-positive cancer will receive the vaccines and pembrolizumab. The goal is to see if this combination shrinks tumors and improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC OROPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama Birmingham
RECRUITINGBirmingham, Alabama, 35249, United States
Contact
Contact
-
Vanderbilt University/Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.